Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

New Targets and Strategies of Medical Treatments in Neurological and Neurodegenerative Disorders

Author(s): Antoni Camins and Carlos Beas-Zarate

Volume 26, Issue 12, 2020

Page: [1233 - 1234] Pages: 2

DOI: 10.2174/138161282612200506115405

Next »
[1]
Sánchez López E, Lopez Machado AL, Vidal LB, Pizarro RG, Silva AD, Souto EB. Lipid nanoparticles as carriers for the treatment of neurodegeneration associated with Alzheimer’s disease and glaucoma: present and future challenges. Curr Pharm Des 2020; 26(12): 1235-50.
[2]
Binvignat O, Olloquequi J. Excitotoxicity as a target against neurodegenerative processes. Curr Pharm Des 2020; 26(12): 1251-62.
[3]
Ureña-Guerrero ME, Castañeda-Cabral JL, Rivera-Cervantes MC, et al. Neuroprotective and Neurestorative Effects of Epo and VEGF: Perspectives for New Therapeutic Approaches to Neurological Diseases. Curr Pharm Des 2020; 26(12): 1263-76.
[4]
Maldonado C, Vázquez M, Fagiolino P. Potential therapeutic role of carnitine and acetylcarnitine in neurological disorders. Curr Pharm Des 2020; 26(12): 1277-85.
[5]
Ettcheto M, Busquets O, Espinosa-Jiménez T, Verdaguer E, Auladell C, Camins A. Chronological review of potential disease modifying therapeutic strategies for Alzheimer’s disease. Curr Pharm Des 2020; 26(12): 1286-99.
[6]
Manzine PR, Vatanabe IP, Peron R, et al. Blood-based biomarkers of Alzheimer’s disease: the long and winding road. Curr Pharm Des 2020; 26(12): 1300-15.
[7]
Cano A, Espina M, García ML. Recent advances on anti-tumor agents-loaded polymeric and lipid based nano-carriers for the treatment of brain cancer. Curr Pharm Des 2020; 26(12): 1316-30.
[8]
Bahadur S, Sachan N, Harwansh RK, Deshmukh R. Nanoparticlized system: promising approach for the management of Alzheimer’s disease through intranasal delivery. Curr Pharm Des 2020; 26(12): 1331-44.
[9]
Casadesus G, Servizi S, Corrigan R. The Importance of understanding amylin signaling mechanisms for therapeutic development in the treatment of Alzheimer’s disease. Curr Pharm Des 2020; 26(12): 1345-55.
[10]
Auzmendi J, Puchulu MB, Garcia Rodriguez JC, Balaszczuk AM, Lazarowski A, Merelli A. EPO and EPO-Receptor system as potential actionable mechanism to protection of brain and heart in refractory epilepsy and SUDEP. Curr Pharm Des 2020; 26(12): 1356-64.
[11]
Jara-Moreno D, Riveros A, Barriga A, Kogan MJ, Delporte C. Inhibition of β-amyloid aggregation of Ugni molinae extracts. Curr Pharm Des 2020; 26(12): 1365-76.
[12]
Montiel T, Montes-Ortega LA, Flores-Yáñez S, Massieu L. Treatment with the ketone body D-β-hydroxybutyrate attenuates autophagy activated by NMDA and reduces excitotoxic neuronal damage in the rat striatum in vivo. Curr Pharm Des 2020; 26(12): 1377-87.
[13]
Vega-García A, Rocha L, Guevara-Guzmán R, Guerra-Araiza C, et al. Magnolia officinalis Reduces inflammation and damage induced by recurrent status epilepticus in immature rats. Curr Pharm Des 2020; 26(12): 1388-401.

Rights & Permissions Print Cite
Article Metrics
22
2
© 2024 Bentham Science Publishers | Privacy Policy